

tuberculosis in Europe

A Bentzon¹, A Pantelev², V Mitsura³, E Borodulina⁴, A Skrahina⁵, E Derisova⁶, S Tetradov⁷, R Podlasin⁸, V Riektina⁹, Z Kancauskiene¹⁰, D Paduta¹¹, A Mocroft¹², T Trofimova¹³, R Miller¹⁴, F Post¹⁵, A Grezesczuk¹⁶, JD Lundgren¹, M Ingot¹⁷, D Podlekareva¹, N Bolokadze¹⁸, O Kirk¹ and the TB:HIV Study Group*.

¹Department of Infectious Disease, Rigshospitalet, University of Copenhagen, Denmark. ²Department of HIV/TB, TB hospital 2, St Petersburg, Russia. ³Gomel State Medical University, Gomel, Belarus. ⁴Department of Phthisiology and pulmonology, Samara state medical University of Minzdrav of Russia, Samara, Russia. ⁵Republican Research and Practical Clinic for Pulmonology, Minsk, Belarus. ⁶Botkin Hospital of Infectious Disease, St. Petersburg, Russia. ⁷Dr. Victor Babes Hospital, Bucharest, Romania. ⁸Wojewodski Szpital Zakazny/Medical University of Warsaw, Warsaw, Poland. ⁹Clinic of TB and Lung Diseases, Riga, Latvia. ¹⁰Clinic for Communicable Diseases and AIDS, Vilnius, Lithuania. ¹¹Gomel Region Clinic for Hygiene, Svetlogorsk, Belarus. ¹²Department of Infection and Population Health, University College London, London, United Kingdom. ¹³Clinic for Prevention and Control of AIDS, Novgorod, Russia. ¹⁴Mortimer Market Clinic, London, United Kingdom. ¹⁵King's College Hospital, London, United Kingdom. ¹⁶Medical University Teaching Hospital, Bialystok, Poland. ¹⁷Wroclaw University School of Medicine, Wroclaw, Poland. ¹⁸Infectious Diseases, AIDS and Clinical Immunology Research Clinic, Tbilisi, Georgia.

METHODS

- ## OBJECTIVE

- ## RESULTS

- ## CONCLUSION

Developments in drug availability within Eastern Europe in 2013 and 2018

Legend: 2013 (n = 21) (Dark Red), 2018 (n = 21) (Light Red)

Top Chart: Availability in 2013 and 2018

Drug	2013 (%)	2018 (%)
Rifabutin	15%	25%
Amikacin	100%	100%
Kanamycin	69%	67%
Capreomycin	39%	64%
Ciprofloxacin	85%	73%
Levofloxacin	69%	92%
Moxifloxacin*	46%	91%

Bottom Chart: Availability in 2013 and 2018

Drug	2013 (%)	2018 (%)
Ofloxacin	75%	73%
Cycloserine	67%	64%
Ethionamide	31%	55%
Prothionamide	63%	82%
Para-aminosalicylic	63%	64%
Linezolid	31%	64%
Bedaquiline	0%	25%

Fig. 3: Developments in drug availability within EE from 2013 to 2018. * $p>0.05$. Data on individual drugs was only included if collected in both studies.




Fig. 1:
Delivery
of Health
Care in
Eastern
and
Western
Europe
* $p < 0.05$.

Fig. 2:
'TB:HIV
Care Score'
in Eastern
and Western
Europe

[illegible]